Animal models for HIV cure research

Frontiers in Immunology

Volumn 7, Issue JAN, 2016, Pages

  Policicchio, Benjamin B ^a   Pandrea, Ivona ^a   Apetrei, Cristian ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Animal models; Cure; FIV; HIV; Humanized mice; Non human primates; SIV; Viral reservoir

Indexed keywords

ALPHA1 INTERFERON; ANTIVIRUS AGENT; BRYOSTATIN; BUTHIONINE SULFOXIMINE; DARUNAVIR PLUS RITONAVIR; DOLUTEGRAVIR; EFAVIRENZ; EMTRICITABINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 21; INTERLEUKIN 7; MARAVIROC; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROSTRATIN; RALTEGRAVIR; RIFAXIMIN; RNA DIRECTED DNA POLYMERASE; SALAZOSULFAPYRIDINE; SEVELAMER; TENOFOVIR; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL MODEL; ANTIVIRAL THERAPY; CD4+ T LYMPHOCYTE; CLINICAL RESEARCH; DISEASE CARRIER; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; MOUSE; NONHUMAN; PATHOGENESIS; PRIMATE; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; STEM CELL TRANSPLANTATION; T LYMPHOCYTE ACTIVATION; VIRUS LATENCY; VIRUS REPLICATION;

EID: 84958162779     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2016.00012     Document Type: Review

References (197)

1. Deeks SG, Autran B, Berkhout B, Benkirane M, Cairns S, Chomont N, et al. Towards an HIV cure: a global scientific strategy. Nat Rev Immunol (2012) 12(8):607-14. doi: 10.1038/nri3262
2. Hogg R, Lima V, Sterne J, Grabar S, Battegay M, Monforte A, et al. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet (2008) 372(9635):293-9. doi:10.1016/S0140-6736(08)61113-7
3. Shen L, Siliciano RF. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection. J Allergy Clin Immunol (2008) 122(1):22-8. doi:10.1016/j.jaci.2008.05.033
4. Pomerantz RJ, Zhang H. Residual HIV-1 persistence during suppressive HAART. Curr Clin Top Infect Dis (2001) 21:1-30.
5. Chomont N, El-Far M, Ancuta P, Trautmann L, Procopio FA, Yassine-Diab B, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med (2009) 15(8):893-900. doi:10.1038/nm.1972
6. Smith DM, Wong JK, Shao H, Hightower GK, Mai HT, Moreno JM, et al. Long-term persistence of transmitted HIV drug resistance in male genital tract secretions: implications for secondary transmission. J Infect Dis (2007) 196(3):356-60. doi:10.1086/519164
7. Chavez L, Calvanese V, Verdin E. HIV latency is established directly and early in both resting and activated primary CD4 T cells. PLoS Pathog (2015) 11(6):e1004955. doi:10.1371/journal.ppat.1004955
8. Ruelas DS, Greene WC. An integrated overview of HIV-1 latency. Cell (2013) 155(3):519-29. doi:10.1016/j.cell.2013.09.044
9. Zink MC, Brice AK, Kelly KM, Queen SE, Gama L, Li M, et al. SIV-infected macaques treated with highly active antiretroviral therapy (HAART) have reduced CNS virus replication and inflammation but persistence of viral DNA. J Infect Dis (2010) 202(1):161-70. doi:10.1086/653213
10. Clements JE, Li M, Gama L, Bullock B, Carruth LM, Mankowski JL, et al. The central nervous system is a viral reservoir in simian immunodeficiency virus-infected macaques on combined antiretroviral therapy: a model for human immunodeficiency virus patients on highly active antiretroviral therapy. J Neurovirol (2015) 11(2):180-9. doi:10.1080/13550280590922748-1
11. Damouche A, Lazure T, vettand-Fènoël VA, Huot N, Dejucq-Rainsford N, Satie AP, et al. Adipose tissue is a neglected viral reservoir and an inflammatory site during chronic HIV and SIV infection. PLoS Pathog (2015) 11(9):e1005153. doi:10.1371/journal.ppat.1005153
12. North TW, Higgins J, Deere JD, Hayes TL, Villalobos A, Adamson L, et al. Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol (2010) 84(6):2913-22. doi:10.1128/JVI.02356-09
13. Kline C, Ndjomou J, Franks T, Kiser R, Coalter V, Smedley J, et al. Persistence of viral reservoirs in multiple tissues after antiretroviral therapy suppression in a macaque RT-SHIV model. PLoS One (2013) 8(12):e84275. doi:10.1371/journal.pone.0084275
14. Xu H, Xiaolei W, Naomi M, Pyone PA, Xavier A, Andrew AL, et al. Persistent SIV infection drives differentiation, aberrant accumulation, and latent infection of germinal center follicular T helper cells. J Virol (2015) 90(3):1578-87. doi:10.1128/JVI.02471-15
15. Buzon MJ, Sun H, Li C, Shaw A, Seiss K, Ouyang Z, et al. HIV-1 persistence in CD4+ T cells with stem cell-like properties. Nat Med (2014) 20(2):139. doi:10.1038/nm.3445
16. Jaafoura S, de Goër de Herve MG, Hernandez-Vargas EA, Hendel-Chavez H, Abdoh M, Mateo MC, et al. Progressive contraction of the latent HIV reservoir around a core of less-differentiated CD4+ memory T cells. Nat Commun (2014) 5:5407. doi:10.1038/ncomms6407
17. Tran TA, de Goër de Herve MG, Hendel-Chavez H, Dembele B, Névot EL, Abbed K, et al. Resting regulatory CD4 T cells: a site of HIV persistence in patients on long-term effective antiretroviral therapy. PLoS One (2008) 3(10):e3305. doi:10.1371/journal.pone.0003305
18. Igarashi T, Brown CR, Endo Y, Buckler-White A, Plishka R, Bischofberger N, et al. Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): implications for HIV-1 infections of humans. Proc Natl Acad Sci U S A (2001) 98(2):658-63. doi:10.1073/pnas.98.2.658
19. Brown D, Mattapallil JJ. Gastrointestinal tract and the mucosal macrophage reservoir in HIV infection. Clin Vaccine Immunol (2014) 21(11):1469. doi:10.1128/CVI.00518-14
20. Micci L, Alvarez X, Iriele RI, Ortiz AM, Ryan ES, McGary CS, et al. CD4 depletion in SIV-infected macaques results in macrophage and microglia infection with rapid turnover of infected cells. PLoS Pathog (2014) 10(10):e1004467. doi:10.1371/journal.ppat.1004467
21. Jochems SP, Jacquelin B, Chauveau L, Huot N, Petitjean G, Lepelley A, et al. Plasmacytoid dendritic cell infection and sensing capacity during pathogenic and nonpathogenic simian immunodeficiency virus infection. J Virol (2015) 89(13):6918-27. doi:10.1128/JVI.00332-15
22. Donaghy H, Gazzard B, Gotch F, Patterson S. Dysfunction and infection of freshly isolated blood myeloid and plasmacytoid dendritic cells in patients infected with HIV-1. Blood (2003) 101(11):4505-11. doi:10.1182/blood-2002-10-3189
23. Fong L, Mengozzi M, Abbey NW, Herndier BG, Engleman EG. Productive infection of plasmacytoid dendritic cells with human immunodeficiency virus type 1 is triggered by CD40 ligation. J Virol (2002) 76(21):11033-41. doi:10.1128/JVI.76.21.11033-11041.2002
24. Patterson S, Rae A, Hockey N, Gilmour J, Gotch F. Plasmacytoid dendritic cells are highly susceptible to human immunodeficiency virus type 1 infection and release infectious virus. J Virol (2001) 75(14):6710-3. doi:10.1128/JVI.75.14.6710-6713.2001
25. Smed-Sörensen A, Loré K, Vasudevan J, Louder MK, Andersson J, Mascola JR, et al. Differential susceptibility to human immunodeficiency virus type 1 infection of myeloid and plasmacytoid dendritic cells. J Virol (2005) 79(14):8861-9. doi:10.1128/JVI.79.14.8861-8869.2005
26. Calantone N, Wu F, Klase Z, Deleage C, Perkins M, Matsuda K, et al. Tissue myeloid cells in SIV-infected primates acquire viral DNA through phagocytosis of infected T cells. Immunity (2014) 41(3):493-502. doi:10.1016/j.immuni.2014.08.014
27. Dinoso JB, Rabi S, Blankson JN, Gama L, Mankowski JL, Siliciano RF, et al. A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J Virol (2009) 83(18):9247-57. doi:10.1128/JVI.00840-09
28. Gandhi RT, Bosch RJ, Aga E, Albrecht M, Demeter LM, Dykes C, et al. No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. J Infect Dis (2010) 201(2):293-6. doi:10.1086/649569
29. Luzuriaga K, Gay H, Ziemniak C, Sanborn KB, Somasundaran M, Rainwater-Lovett K, et al. Viremic relapse after HIV-1 remission in a perinatally infected child. N Engl J Med (2015) 372(8):786-8. doi:10.1056/NEJMc1413931
30. Fidler S, Porter K, Ewings F, Frater J, Ramjee G, Cooper D, et al. Short-course antiretroviral therapy in primary HIV infection. N Engl J Med (2013) 368(3):207-17. doi:10.1056/NEJMoa1110039
31. Hocqueloux L, Prazuck T, vettand-Fenoel VA, Lafeuillade A, Cardon B, Viard JP, et al. Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS (2010) 24(10):1598-601. doi:10.1097/QAD.0b013e32833b61ba
32. Hamlyn E, Ewings FM, Porter K, Cooper DA, Tambussi G, Schechter M, et al. Plasma HIV viral rebound following protocol-indicated cessation of ART commenced in primary and chronic HIV infection. PLoS One (2012) 7(8):e43754. doi:10.1371/journal.pone.0043754
33. Pennings PS. Standing genetic variation and the evolution of drug resistance in HIV. PLoS Comput Biol (2012) 8(6):e1002527. doi:10.1371/journal.pcbi.1002527
34. Rothenberger MK, Keele BF, Wietgrefe SW, Fletcher CV, Beilman GJ, Chipman JG, et al. Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption. Proc Natl Acad Sci U S A (2015) 112(10):E1126-34. doi:10.1073/pnas.1414926112
35. Lederman MM, Funderburg NT, Sekaly RP, Klatt NR, Hunt PW. Residual immune dysregulation syndrome in treated HIV infection. Adv Immunol (2013) 119:51-83. doi:10.1016/B978-0-12-407707-2.00002-3
36. Deeks SG, Tracy R, Douek DC. Systemic effects of inflammation on health during chronic HIV infection. Immunity (2013) 39(4):633-45. doi:10.1016/j.immuni.2013.10.001
37. Pandrea I, Landay A, Wilson C, Stock J, Tracy R, Apetrei C. Using the pathogenic and nonpathogenic nonhuman primate model for studying non-AIDS comorbidities. Curr HIV/AIDS Rep (2015) 12(1):54-67. doi:10.1007/s11904-014-0245-5
38. Dinoso JB, Kim SY, Wiegand AM, Palmer SE, Gange SJ, Cranmer L, et al. Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A (2009) 106(23):9403-8. doi:10.1073/pnas.0903107106
39. Gandhi RT, Zheng L, Bosch RJ, Chan ES, Margolis DM, Read S, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med (2010) 7(8):e1000321. doi:10.1371/journal.pmed.1000321
40. Persaud D, Gay H, Ziemniak C, Chen YH, Piatak M, Chun TW, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med (2013) 369(19):1828-35. doi:10.1056/NEJMoa1302976
41. Siliciano JD, Siliciano RF. Rekindled HIV infection. Science (2014) 345(6200):1005-6. doi:10.1126/science.1259452
42. Rouzioux C, Hocqueloux L, Sáez-Cirión AS. Posttreatment controllers: what do they tell us? Curr Opin HIV AIDS (2015) 10(1):29-34. doi:10.1097/COH.0000000000000123
43. Sáez-Cirión A, Bacchus C, Hocqueloux L, vettand-Fenoel VA, Girault I, Lecuroux C, et al. Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study. PLoS Pathog (2013) 9(3):e1003211. doi:10.1371/journal.ppat.1003211
44. Hütter G, Nowak D, Mossner M, Ganepola S, Müßig A, Allers K, et al. Long-term control of HIV by CCR5 delta32/delta32 stem-cell transplantation. N Engl J Med (2009) 360(7):692-8. doi:10.1056/NEJMoa0802905
45. Henrich TJ, Hu Z, Li JZ, Sciaranghella G, Busch MP, Keating SM, et al. Long-term reduction in peripheral blood HIV type 1 reservoirs following reduced-intensity conditioning allogeneic stem cell transplantation. J Infect Dis (2013) 207(11):1694-702. doi:10.1093/infdis/jit086
46. Check Hayden E. Hopes of HIV cure in 'Boston patients' dashed. Nat News (2015). doi:10.1038/nature.2013.14324
47. Fauci AS, Desrosiers RC. Pathogenesis of HIV and SIV. In: John MC, Stephen HH, Harold HV, editors. Retroviruses. New York: Cold Spring Harbor Laboratory Press (1997). Available from: http://www.ncbi.nlm.nih.gov/books/NBK19359/
48. Evans DT, Silvestri G. Non-human primate models in AIDS research. Curr Opin HIV AIDS (2013) 8(4):255-61. doi:10.1097/COH.0b013e328361cee8
49. Del Prete GQ, Lifson JD. Considerations in the development of nonhuman primate models of combination antiretroviral therapy for studies of AIDS virus suppression, residual virus, and curative strategies. Curr Opin HIV AIDS (2013) 8(4):262-72. doi:10.1097/COH.0b013e328361cf40
50. Akkina R. New generation humanized mice for virus research: comparative aspects and future prospects. Virology (2013) 435(1):14-28. doi:10.1016/j.virol.2012.10.007
51. McDonnel SJ, Sparger EE, Murphy BG. Feline immunodeficiency virus latency. Retrovirology (2013) 10(July):69. doi:10.1186/1742-4690-10-69
52. Apetrei C, Pandrea I, Mellors JW. Nonhuman primate models for HIV cure research. PLoS Pathog (2012) 8(8):e1002892. doi:10.1371/journal.ppat.1002892
53. Sui Y, Gordon S, Franchini G, Berzofsky JA. Non-human primate models for HIV/AIDS vaccine development. Curr Protoc Immunol (2013) 102(12.14):1-30. doi:10.1002/0471142735.im1214s102
54. Van Rompay KKA. Evaluation of antiretrovirals in animal models of HIV infection. Antiviral Res (2010) 85(1):159-75. doi:10.1016/j.antiviral.2009.07.008
55. Gardner MB, Luciw PA. Macaque models of human infectious disease. ILAR J (2008) 49(2):220-55. doi:10.1093/ilar.49.2.220
56. Haase AT. Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu Rev Med (2011) 62(1):127-39. doi:10.1146/annurev-med-080709-124959
57. Lackner AA, Veazey RS. Current concepts in AIDS pathogenesis: insights from the SIV/macaque model. Annu Rev Med (2007) 58(1):461-76. doi:10.1146/annurev.med.58.082405.094316
58. Demberg T, Brocca-Cofano E, Xiao P, Venzon D, Vargas-Inchaustegui D, Mi Lee E, et al. Dynamics of memory B-cell populations in blood, lymph nodes, and bone marrow during antiretroviral therapy and envelope boosting in simian immunodeficiency virus SIVmac251-infected rhesus macaques. J Virol (2012) 86(23):12591-604. doi:10.1128/JVI.00298-12
59. Horiike M, Iwami S, Kodama M, Sato A, Watanabe Y, Yasui M, et al. Lymph nodes harbor viral reservoirs that cause rebound of plasma viremia in SIV-infected macaques upon cessation of combined antiretroviral therapy. Virology (2012) 423(2):107-18. doi:10.1016/j.virol.2011.11.024
60. Pandrea I, Gaufin T, Gautam R, KristoffJ, Mandell D, Montefiori D, et al. Functional cure of SIVagm infection in rhesus macaques results in complete recovery of CD4+ T cells and is reverted by CD8+ cell depletion. PLoS Pathog (2011) 7(8):e1002170. doi:10.1371/journal.ppat.1002170
61. Ma D, Xu C, Cillo AR, Policicchio B, KristoffJ, Haret-Richter G, et al. Simian immunodeficiency virus SIVsab infection of rhesus macaques as a model of complete immunological suppression with persistent reservoirs of replication-competent virus: implications for cure research. J Virol (2015) 89(11):6155-60. doi:10.1128/JVI.00256-15
62. Uberla K, Stahl-Hennig C, Böttiger D, Ätz-Rensing KM, Kaup FJ, Li J, et al. Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors. Proc Natl Acad Sci U S A (1995) 92(18):8210-4. doi:10.1073/pnas.92.18.8210
63. North TW, Koen KA, Rompay V, Higgins J, Matthews TB, Wadford DA, et al. Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from human immunodeficiency virus type 1. J Virol (2005) 79(12):7349. doi:10.1128/JVI.79.12.7349-7354.2005
64. Kauffman RC, Villalobos A, Bowen JH, Adamson L, Schinazi RF. Residual viremia in an RT-SHIV rhesus macaque HAART model marked by the presence of a predominant plasma clone and a lack of viral evolution. PLoS One (2014) 9(2):e88258. doi:10.1371/journal.pone.0088258
65. Monceaux V, Viollet L, Petit F, Cumont MC, Kaufmann GR, Aubertin AM, et al. CD4+ CCR5+ T-cell dynamics during simian immunodeficiency virus infection of Chinese rhesus macaques. J Virol (2007) 81(24):13865-75. doi:10.1128/JVI.00452-07
66. Ling B, Veazey RS, Luckay A, Penedo C, Xu K, Lifson JD, et al. SIVmac pathogenesis in rhesus macaques of Chinese and Indian origin compared with primary HIV infections in humans. J Med Primatol (2002) 31(4-5):154-63. doi:10.1034/j.1600-0684.2002.02001.x
67. Ling B, Piatak M Jr, Rogers L, Johnson A-M, Russell-Lodrigue K, Hazuda DJ, et al. Effects of treatment with suppressive combination antiretroviral drug therapy and the histone deacetylase inhibitor suberoylanilide hydroxamic acid; (SAHA) on SIV-infected Chinese rhesus macaques. PLoS One (2014) 9(7):e102795. doi:10.1371/journal.pone.0102795
68. Klatt NR, Canary LA, Vanderford TH, Vinton CL, Engram JC, Dunham RM, et al. Dynamics of simian immunodeficiency virus SIVmac239 infection in pigtail macaques. J Virol (2012) 86(2):1203-13. doi:10.1128/JVI.06033-11
69. Canary LA, Vinton CL, Morcock DR, Pierce JB, Estes JD, Brenchley JM, et al. Rate of AIDS progression is associated with gastrointestinal dysfunction in SIV-infected pigtail macaques. J Immunol (2013) 190(6):2959. doi:10.4049/jimmunol.1202319
70. Hirsch VM, Dapolito G, Johnson PR, Elkins WR, London WT, Montali RJ, et al. Induction of AIDS by simian immunodeficiency virus from an African green monkey: species-specific variation in pathogenicity correlates with the extent of in vivo replication. J Virol (1995) 69(2):955-67.
71. Mandell DT, KristoffJ, Gaufin T, Gautam R, Ma D, Sandler N, et al. Pathogenic features associated with increased virulence upon simian immunodeficiency virus cross-species transmission from natural hosts. J Virol (2014) 88(12):6778-92. doi:10.1128/JVI.03785-13
72. KristoffJ, Haret-Richter G, Ma D, Ribeiro RM, Xu C, Cornell E, et al. Early microbial translocation blockade reduces SIV-mediated inflammation and viral replication. J Clin Invest (2014) 124(6):2802-6. doi:10.1172/JCI75090
73. Ambrose Z, Palmer S, Boltz VF, Kearney M, Larsen K, Polacino P, et al. Suppression of viremia and evolution of human immunodeficiency virus type 1 drug resistance in a macaque model for antiretroviral therapy. J Virol (2007) 81(22):12145-55. doi:10.1128/JVI.01301-07
74. Shao W, Kearney M, Maldarelli F, Mellors JW, Stephens RM, Lifson JD, et al. RT-SHIV subpopulation dynamics in infected macaques during anti-HIV therapy. Retrovirology (2009) 6(November):101. doi:10.1186/1742-4690-6-101
75. Kearney M, Spindler J, Shao W, Maldarelli F, Palmer S, Hu S-L, et al. Genetic diversity of simian immunodeficiency virus encoding HIV-1 reverse transcriptase persists in macaques despite antiretroviral therapy. J Virol (2011) 85(2):1067-76. doi:10.1128/JVI.01701-10
76. Benlhassan-Chahour K, Penit C, Dioszeghy V, Vasseur F, Janvier G, Rivière Y, et al. Kinetics of lymphocyte proliferation during primary immune response in macaques infected with pathogenic simian immunodeficiency virus SIVmac251: preliminary report of the effect of early antiviral therapy. J Virol (2003) 77(23):12479-93. doi:10.1128/JVI.77.23.12479-12493.2003
77. Mannioui A, Bourry O, Sellier P, Delache B, Brochard P, Andrieu T, et al. Dynamics of viral replication in blood and lymphoid tissues during SIVmac251 infection of macaques. Retrovirology (2009) 6(1):106. doi:10.1186/1742-4690-6-106
78. Sellier P, Mannioui A, Bourry O, Dereuddre-Bosquet N, Delache B, Brochard P, et al. Antiretroviral treatment start-time during primary SIV(mac) infection in macaques exerts a different impact on early viral replication and dissemination. PLoS One (2010) 5(5):e10570. doi:10.1371/journal.pone.0010570
79. Reimann KA, Parker RA, Seaman MS, Beaudry K, Beddall M, Peterson L, et al. Pathogenicity of simian-human immunodeficiency virus SHIV-89.6P and SIVmac is attenuated in cynomolgus macaques and associated with early T-lymphocyte responses. J Virol (2005) 79(14):8878. doi:10.1128/JVI.79.14.8878-8885.2005
80. Budde ML, Greene JM, Chin EN, Ericsen AJ, Scarlotta M, Cain BT, et al. Specific CD8+ T cell responses correlate with control of simian immunodeficiency virus replication in Mauritian cynomolgus macaques. J Virol (2012) 86(14):7596. doi:10.1128/JVI.00716-12
81. Pandrea I, Apetrei C. Where the wild things are: pathogenesis of SIV infection in African nonhuman primate hosts. Curr HIV/AIDS Rep (2010) 7(1):28. doi:10.1007/s11904-009-0034-8
82. VandeWoude S, Apetrei C. Going wild: lessons from naturally occurring T-lymphotropic lentiviruses. Clin Microbiol Rev (2006) 19(4):728-62. doi:10.1128/CMR.00009-06
83. Sodora DL, Allan JS, Apetrei C, Brenchley JM, Douek DC, Else JG, et al. Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts. Nat Med (2009) 15(8):861-5. doi:10.1038/nm.2013
84. Chahroudi A, Bosinger SE, Vanderford TH, Paiardini M, Silvestri G. Natural SIV hosts: showing AIDS the door. Science (2012) 335(6073). doi:10.1126/science.1217550
85. Nishimura Y, Sadjadpour R, Mattapallil JJ, Igarashi T, Lee W, Buckler-White A, et al. High frequencies of resting CD4+ T cells containing integrated viral DNA are found in rhesus macaques during acute lentivirus infections. Proc Natl Acad Sci U S A (2009) 106(19):8015-20. doi:10.1073/pnas.0903022106
86. Shen AM, Zink C, Mankowski JL, Chadwick K, Margolick JB, Carruth LM, et al. Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy. J Virol (2003) 77(8):4938-49. doi:10.1128/JVI.77.8.4938-4949.2003
87. Crise B, Li Y, Yuan C, Morcock DR, Whitby D, Munroe DJ, et al. Simian immunodeficiency virus integration preference is similar to that of human immunodeficiency virus type 1. J Virol (2005) 79(19):12199-204. doi:10.1128/JVI.79.19.12199-12204.2005
88. Barber SA, Gama L, Dudaronek JM, Voelker T, Tarwater PM, Clements JE. Mechanism for the establishment of transcriptional HIV latency in the brain in a simian immunodeficiency virus-macaque model. J Infect Dis (2006) 193(7):963-70. doi:10.1086/500983
89. Shen A, Yang H-C, Zhou Y, Chase AJ, Boyer JD, Zhang H, et al. Novel pathway for induction of latent virus from resting CD4+ T cells in the simian immunodeficiency virus/macaque model of human immunodeficiency virus type 1 latency. J Virol (2007) 81(4):1660-70. doi:10.1128/JVI.01396-06
90. Bourry O, Mannioui A, Sellier P, Roucairol C, Durand-Gasselin L, Dereuddre-Bosquet N, et al. Effect of a short-term HAART on SIV load in macaque tissues is dependent on time of initiation and antiviral diffusion. Retrovirology (2010) 7:78. doi:10.1186/1742-4690-7-78
91. Chen, Zheng W, Craiu A, Shen L, Kuroda MJ, Iroku UC, et al. Simian immunodeficiency virus evades a dominant epitope-specific cytotoxic T lymphocyte response through a mutation resulting in the accelerated dissociation of viral peptide and MHC class I. J Immunol (2000) 164(12):6474-9. doi:10.4049/jimmunol.164.12.6474
92. Goulder PJR, Watkins DI. HIV and SIV CTL escape: implications for vaccine design. Nat Rev Immunol (2004) 4(8):630-40. doi:10.1038/nri1417
93. Ren J, Bird LE, Chamberlain PP, Stewart-Jones GB, Stuart DI, Stammers DK. Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc Natl Acad Sci U S A (2002) 99(22):14410-5. doi:10.1073/pnas.222366699
94. Debyser Z, De Vreese K, Pauwels R, Yamamoto N, Anne J, De Clercq E, et al. Differential inhibitory effects of TIBO derivatives on different strains of simian immunodeficiency virus. J Gen Virol (1992) 73(7):1799-804. doi:10.1099/0022-1317-73-7-1799
95. Witvrouw M, Pannecouque C, Van Laethem K, Desmyter J, De Clercq E, Vandamme AM. Activity of non-nucleoside reverse transcriptase inhibitors against HIV-2 and SIV. AIDS (1999) 13(12):1477-83. doi:10.1097/00002030-199908200-00006
96. Hatziioannou T, Evans DT. Animal models for HIV/AIDS research. Nat Rev Microbiol (2012) 10(12):852-67. doi:10.1038/nrmicro2911
97. Shytaj IL, Norelli S, Chirullo B, Corte AD, Collins M, Yalley-Ogunro J, et al. "A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model." Edited by Guido Silvestri. PLoS Pathog (2012) 8(6):e1002774. doi:10.1371/journal.ppat.1002774
98. Witvrouw M, Pannecouque C, Switzer WM, Folks TM, De Clercq E, Heneine W. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther (2004) 9(1):57-65.
99. Gaufin T, Gautam R, Kasheta M, Ribeiro R, Ribka E, Barnes M, et al. Limited ability of humoral immune responses in control of viremia during infection with SIVsmmD215 strain. Blood (2009) 113(18):4250-61. doi:10.1182/blood-2008-09-177741
100. Brandariz-Nuñez A, Valle-Casuso JC, White TE, Laguette N, Benkirane M, Brojatsch J, et al. Role of SAMHD1 nuclear localization in restriction of HIV-1 and SIVmac. Retrovirology (2012) 9(June):49. doi:10.1186/1742-4690-9-49
101. Baldauf HM, Pan X, Erikson E, Schmidt S, Daddacha W, Burggraf M, et al. SAMHD1 restricts HIV-1 infection in resting CD4+ T Cells. Nat Med (2012) 18(11). doi:10.1038/nm.2964
102. Descours B, Cribier A, Chable-Bessia C, Ayinde D, Rice G, Crow Y, et al. SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4+ T-cells. Retrovirology (2012) 9(October):87. doi:10.1186/1742-4690-9-87
103. Goujon C, Rivière L, Jarrosson-Wuilleme L, Bernaud J, Rigal D, Darlix J-L, et al. SIVSM/HIV-2 Vpx proteins promote retroviral escape from a proteasome-dependent restriction pathway present in human dendritic cells. Retrovirology (2007) 4(January):2. doi:10.1186/1742-4690-4-2
104. Tristem M, Marshall C, Karpas A, Hill F. Evolution of the primate lentiviruses: evidence from Vpx and Vpr. EMBO J (1992) 11(9):3405-12.
105. Goujon C, Jarrosson-Wuillème L, Bernaud J, Rigal D, Darlix J-L, Cimarelli A. With a little help from a friend: increasing HIV transduction of monocyte-derived dendritic cells with virion-like particles of SIVMAC. Gene Ther (2006) 13(12):991-4. doi:10.1038/sj.gt.3302753
106. Sunseri N, O'Brien M, Bhardwaj N, Landau NR. Human immunodeficiency virus type 1 modified to package Simian immunodeficiency virus Vpx efficiently infects macrophages and dendritic cells. J Virol (2011) 85(13):6263-74. doi:10.1128/JVI.00346-11
107. Simon V, Bloch N, Landau NR. Intrinsic host restrictions to HIV-1 and mechanisms of viral escape. Nat Immunol (2015) 16(6):546-53. doi:10.1038/ni.3156
108. Ling B, Rogers L, Johnson A-M, Piatak M, Lifson J, Veazey RS. Effect of combination antiretroviral therapy on Chinese rhesus macaques of simian immunodeficiency virus infection. AIDS Res Hum Retroviruses (2013) 29(11):1465-74. doi:10.1089/AID.2012.0378
109. Zink MC, Suryanarayana K, Mankowski JL, Shen A, Piatak M, Spelman JP, et al. High viral load in the cerebrospinal fluid and brain correlates with severity of simian immunodeficiency virus encephalitis. J Virol (1999) 73(12):10480-8.
110. Graham DR, Gama L, Queen SE, Li M, Brice AK, Kelly KM, et al. Initiation of HAART during acute simian immunodeficiency virus infection rapidly controls virus replication in the CNS by enhancing immune activity and preserving protective immune responses. J Neurovirol (2011) 17(1):120-30. doi:10.1007/s13365-010-0005-2
111. Balzarini J, Weeger M, Camarasa MJ, Declercq E, Uberla K. Sensitivity/resistance profile of a simian immunodeficiency virus containing the reverse transcriptase gene of human immunodeficiency virus type 1 (HIV-1) toward the HIV-1-specific non-nucleoside reverse transcriptase inhibitors. Biochem Biophys Res Commun (1995) 211(3):850-6. doi:10.1006/bbrc.1995.1890
112. Del Prete GQ, Ailers B, Moldt B, Keele BF, Estes JD, Rodriguez A, et al. Selection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteins. Cell Host Microbe (2014) 16(3):412-8. doi:10.1016/j.chom.2014.08.003
113. Shan L, Deng K, ShroffNS, Durand CM, Rabi SA, Yang HC, et al. Stimulation of HIV-1-specific cytolytic T-lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity (2012) 36(3):491-501. doi:10.1016/j.immuni.2012.01.014
114. Ma D, Jasinska AJ, Feyertag F, Wijewardana V, KristoffJ, He T, et al. Factors associated with siman immunodeficiency virus transmission in a natural African nonhuman primate host in the wild. J Virol (2014) 88(10):5687-705. doi:10.1128/JVI.03606-13
115. Del Prete GQ, Smedley J, Macallister R, Jones G, Li B, Hattersley J, et al. Comparative evaluation of co-formulated injectable combination antiretroviral therapy regimens in SIV-infected rhesus macaques. AIDS Res Hum Retroviruses (2015) 31:1-6. doi:10.1089/AID.2015.0130
116. Whitney JB, Hill AL, Sanisetty S, MacMaster PP, Liu J, Shetty M, et al. Rapid seeding of the viral reservoir prior to SIV viremia in rhesus monkeys. Nature (2014) 512(7512):74-7. doi:10.1038/nature13594
117. Hilldorfer BB, Cillo AR, Besson GJ, Bedison MA, Mellors JW. New tools for quantifying HIV-1 reservoirs: plasma RNA single copy assays and beyond. Curr HIV/AIDS Rep (2012) 9(1):91-100. doi:10.1007/s11904-011-0104-6
118. Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med (1999) 5(5):512-7. doi:10.1038/8394
119. Shiu C, Cunningham CK, Greenough T, Muresan P, Sanchez-Merino V, Carey V, et al. Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretroviral therapy. J Virol (2009) 83(19):9731-42. doi:10.1128/JVI.00570-09
120. Palmer S, Maldarelli F, Wiegand A, Bernstein B, Hanna GJ, Brun SC, et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A (2008) 105(10):3879-84. doi:10.1073/pnas.0800050105
121. Bailey, Justin R, Ahmad R, Sedaghat, Tara Kieffer, Timothy Brennan, et al. Residual human immunodeficiency virus Type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol (2006) 80(13):6441-57. doi:10.1128/JVI.00591-06
122. Ambrose Z, Boltz VF, Palmer S, Coffin JM, Hughes SH, KewalRamani VN. In vitro characterization of a simian immunodeficiency virus-human immunodeficiency virus (HIV) chimera expressing HIV type 1 reverse transcriptase to study antiviral resistance in pigtail macaques. J Virol (2004) 78(24):13553-61. doi:10.1128/JVI.78.24.13553-13561.2004
123. Kearney MF, Anderson EM, Coomer C, Smith L, Shao W, Johnson N, et al. Well-mixed plasma and tissue viral populations in RT-SHIV-infected macaques implies a lack of viral replication in the tissues during antiretroviral therapy. Retrovirology (2015) 12:93. doi:10.1186/s12977-015-0212-2
124. Prete GQ, Shoemaker DR, Oswald K, Lara A, Trubey CM, Fast R, et al. Effect of suberoylanilide hydroxamic acid (SAHA) administration on the residual virus pool in a model of combination antiretroviral therapy-mediated suppression in SIVmac239-infected Indian rhesus macaques. Antimicrob Agents Chemother (2014) 58(11):6790-806. doi:10.1128/AAC.03746-14
125. Jones RB, O'Connor R, Mueller S, Foley M, Szeto GL, Karel D, et al. "Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes." Edited by Guido Silvestri. PLoS Pathog (2014) 10(8):e1004287. doi:10.1371/journal.ppat.1004287
126. Lewis MG, DaFonseca S, Chomont N, Palamara AT, Tardugno M, Mai A, et al. Gold drug auranofin restricts the viral reservoir in the monkey AIDS model and induces containment of viral load following ART suspension. AIDS (2011) 25(11):1347-56. doi:10.1097/QAD.0b013e328347bd77
127. Shytaj IL, Nickel G, Arts E, Farrell N, Biffoni M, Pal R, et al. A two-year follow-up of macaques developing intermittent control of the HIV homolog SIVmac251 in the chronic phase of the infection. J Virol (2015) 89(15):7521-35. doi:10.1128/JVI.00396-15
128. Shytaj IL, Chirullo B, Wendeline Wagner, Maria G, Ferrari, Rossella Sgarbanti, et al. Investigational treatment suspension and enhanced cell-mediated immunity at rebound followed by drug-free remission of simian AIDS. Retrovirology (2013) 10(1):71. doi:10.1186/1742-4690-10-71
129. Mavigner M, Watkins B, Lawson B, Lee ST, Chahroudi A, Kean L, et al. Persistence of virus reservoirs in ART-treated SHIV-infected rhesus macaques after autologous hematopoietic stem cell transplant. PLoS Pathog (2014) 10(9):e1004406. doi:10.1371/journal.ppat.1004406
130. Volberding PA, Deeks SG. Antiretroviral therapy and management of HIV infection. Lancet (2010) 376(9734):49-62. doi:10.1016/S0140-6736(10)60676-9
131. Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet (2013) 382(9903):1525-33. doi:10.1016/S0140-6736(13)61809-7
132. Li Q, Duan L, Estes JD, Ma Z-M, Rourke T, Wang Y, et al. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature (2005) 434(7037):1148-52. doi:10.1038/nature03513
133. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med (2006) 12(12):1365-71. doi:10.1038/nm1511
134. Favre D, Lederer S, Kanwar B, Ma Z-M, Proll S, Kasakow Z, et al. Critical loss of the balance between Th17 and T regulatory cell populations in pathogenic SIV infection. PLoS Pathog (2009) 5(2):e1000295. doi:10.1371/journal.ppat.1000295
135. Raffatellu M, Santos RL, David E, Verhoeven, Michael D, George R, et al. Simian immunodeficiency virus-induced mucosal interleukin-17 deficiency promotes Salmonella dissemination from the gut. Nat Med (2008) 14(4):421-8. doi:10.1038/nm1743
136. Brenchley JM, Paiardini M, Knox KS, Asher AI, Cervasi B, Asher TE, et al. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood (2008) 112(7):2826-35. doi:10.1182/blood-2008-05-159301
137. Moreno-Fernandez ME, Presicce P, Chougnet CA. Homeostasis and function of regulatory T cells in HIV/SIV infection. J Virol (2012) 86(19):10262. doi:10.1128/JVI.00993-12
138. Pandrea I, Gaufin T, Brenchley JM, Gautam R, Monjure C, Gautam A, et al. Cutting edge: experimentally induced immune activation in natural hosts of simian immunodeficiency virus induces significant increases in viral replication and CD4+ T cell depletion. J Immunol (2008) 181(10):6687. doi:10.4049/jimmunol.181.10.6687
139. Cecchinato V, Tryniszewska E, Ma ZM, Vaccari M, Boasso A, Tsai W-P, et al. Immune activation driven by CTLA-4 blockade augments viral replication at mucosal sites in simian immunodeficiency virus infection. J Immunol (2008) 180(8):5439-47. doi:10.4049/jimmunol.180.8.5439
140. Estes JD, Wietgrefe S, Schacker T, Southern P, Beilman G, Reilly C, et al. Simian immunodeficiency virus-induced lymphatic tissue fibrosis is mediated by transforming growth factor beta 1-positive regulatory T cells and begins in early infection. J Infect Dis (2007) 195(4):551-61. doi:10.1086/510852
141. Pandrea I, Landay AL. Chapter 3-implications for therapy. In: Pancino G, SilvestriKeith CFR, editors. Models of Protection Against HIV/SIV. Boston: Academic Press (2012). p. 81-132.
142. Vassena L, Miao H, Cimbro R, Malnati MS, Cassina G, Proschan MA, et al. Treatment with IL-7 prevents the decline of circulating CD4+ T cells during the acute phase of SIV infection in rhesus macaques. PLoS Pathog (2012) 8(4):e1002636. doi:10.1371/journal.ppat.1002636
143. Leone A, Rohankhedkhar M, Okoye A, Legasse A, Axthelm MK, Villinger F, et al. Increased CD4+ T cell levels during IL-7 administration of ART treated SIV+ macaques are not dependent on strong proliferative responses. J Immunol (2010) 185(3):1650-9. doi:10.4049/jimmunol.0902626
144. Parker R, Dutrieux J, Beq S, Lemercier B, Rozlan S, Fabre-Mersseman V, et al. Interleukin-7 treatment counteracts IFN-a therapy-induced lymphopenia and stimulates SIV-specific cytotoxic T lymphocyte responses in SIV-infected rhesus macaques. Blood (2010) 116(25):5589-99. doi:10.1182/blood-2010-03-276261
145. Xu H, Wang X, Veazey RS. Th17 cells coordinate with Th22 cells in maintaining homeostasis of intestinal tissues and both are depleted in SIV-infected macaques. J AIDS Clin Res (2014) 5(5):302. doi:10.4172/2155-6113.1000302
146. Micci L, Ryan ES, Fromentin R, Bosinger SE, Harper JL, He T, et al. Interleukin-21 combined with ART reduces inflammation and viral reservoir in SIV-infected macaques. J Clin Invest (2015) 125(12):4497-513. doi:10.1172/JCI81400
147. Ortiz AM, Klase ZA, DiNapoli SR, Vujkovic-Cvijin I, Carmack K, Perkins MR, et al. IL-21 and probiotic therapy improve Th17 frequencies, microbial translocation, and microbiome in ARV-Treated, SIV-infected macaques. Mucosal Immunol (2015). doi:10.1038/mi.2015.75
148. Klatt NR, Canary LA, Sun X, Vinton CL, Funderburg NT, Morcock DR, et al. Probiotic/prebiotic supplementation of antiretrovirals improves gastrointestinal immunity in SIV-infected macaques. J Clin Invest (2013) 123(2):903-7. doi:10.1172/JCI66227
149. Perianayagam MC, Jaber BL. Endotoxin-binding affinity of sevelamer hydrochloride. Am J Nephrol (2008) 28(5):802-7. doi:10.1159/000135691
150. DuPont HL. Therapy for and prevention of traveler's diarrhea. Clin Infect Dis (2007) 45(Suppl 1):S78-84. doi:10.1086/518155
151. Lawrence KR, Klee JA. Rifaximin for the treatment of hepatic encephalopathy. Pharmacotherapy (2008) 28(8):1019-32. doi:10.1592/phco.28.8.1019
152. Pandrea I, Xu C, Stock JL, Frank DN, Ma D, Policicchio BB, et al. Antibiotic and antiinflammatory therapy transiently reduces inflammation and hypercoagulation in acutely SIV-infected pigtailed macaques. PLoS Pathog (2016) 12(1):e1005384. doi:10.1371/journal.ppat.1005384
153. Klatt NR, Harris LD, Vinton CL, Sung H, Briant JA, Tabb B, et al. Compromised gastrointestinal integrity in pigtail macaques is associated with increased microbial translocation, immune activation, and IL-17 production in the absence of SIV infection. Mucosal Immunol (2010) 3(4):387-98. doi:10.1038/mi.2010.14
154. Amara RR, Robinson HL. A new generation of HIV vaccines. Trends Mol Med (2002) 8(10):489-95. doi:10.1016/S1471-4914(02)02401-2
155. Powers C, Früh K. Rhesus CMV: an emerging animal model for human CMV. Med Microbiol Immunol (2008) 197(2):109-15. doi:10.1007/s00430-007-0073-y
156. Hansen SG, Vieville C, Whizin N, Coyne-Johnson L, Siess DC, Drummond DD, et al. Effector-memory T cell responses are associated with protection of rhesus monkeys from mucosal SIV challenge. Nat Med (2009) 15(3):293-9. doi:10.1038/nm.1935
157. Picker LJ, Reed-Inderbitzin EF, Hagen SI, Edgar JB, Hansen SG, Legasse A, et al. IL-15 induces CD4+ effector memory T cell production and tissue emigration in nonhuman primates. J Clin Invest (2006) 116(6):1514-24. doi:10.1172/JCI27564
158. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, et al. Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature (2011) 473(7348):523-7. doi:10.1038/nature10003
159. Hansen SG, Sacha JB, Hughes CM, Ford JC, Burwitz BJ, Scholz I, et al. Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. Science (2013) 340(6135):1237874. doi:10.1126/science.1237874
160. Dudek TE, No DC, Seung E, Vrbanac VD, Fadda L, Bhoumik P, et al. Rapid evolution of HIV-1 to functional CD8+ T Cell responses in humanized BLT mice. Sci Transl Med (2012) 4(143):ra98-143. doi:10.1126/scitranslmed.3003984
161. Olesen R, Wahl A, Denton PW, Garcia JV. Immune reconstitution of the female reproductive tract of humanized BLT mice and their susceptibility to human immunodeficiency virus infection. J Reprod Immunol (2011) 88(2):195-203. doi:10.1016/j.jri.2010.11.005
162. Sun Z, Denton PW, Estes JD, Othieno FA, Wei BL, Wege AK, et al. Intrarectal transmission, systemic infection, and CD4+ T cell depletion in humanized mice infected with HIV-1. J Exp Med (2007) 204(4):705-14. doi:10.1084/jem.20062411
163. Karpel ME, Boutwell CL, Allen TM. BLT humanized mice as a small animal model of HIV infection. Curr Opin Virol (2015) 13(August):75-80. doi:10.1016/j.coviro.2015.05.002
164. Traggiai E, Chicha L, Mazzucchelli L, Bronz L, Piffaretti J-C, Lanzavecchia A, et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science (2004) 304(5667):104-7. doi:10.1126/science.1093933
165. Bonyhadi ML, Kaneshima H. The SCID-hu mouse: an in vivo model for HIV-1 infection in humans. Mol Med Today (1997) 3(6):246-53. doi:10.1016/S1357-4310(97)01046-0
166. Brainard DM, Seung E, Frahm N, Cariappa A, Bailey CC, Hart WK, et al. Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice. J Virol (2009) 83(14):7305-21. doi:10.1128/JVI.02207-08
167. McCune JM, Namikawa R, Kaneshima H, Shultz LD, Lieberman M, Weissman IL. The SCID-Hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science (1988) 241(4873):1632-9. doi:10.1126/science.2971269
168. Nischang M, Gers-Huber G, Audigé A, Akkina R, Speck RF. Modeling HIV infection and therapies in humanized mice. Swiss Med Week (2012) 142:w13618. doi:10.4414/smw.2012.13618
169. Baenziger S, Tussiwand R, Schlaepfer E, Mazzucchelli L, Heikenwalder M, Kurrer MO, et al. Disseminated and sustained HIV infection in CD34+ cord blood cell-transplanted Rag2-/-γc-/-mice. Proc Natl Acad Sci U S A (2006) 103(43):15951-6. doi:10.1073/pnas.0604493103
170. Berges BK, Akkina SR, Remling L, Akkina R. Humanized Rag2-/-γc-/-(RAG-Hu) mice can sustain long-term chronic HIV-1 infection lasting more than a year. Virology (2010) 397(1):100-3. doi:10.1016/j.virol.2009.10.034
171. Pettoello-Mantovani M, Kollmann TR, Katopodis NF, Raker C, Kim A, Yurasov S, et al. Thy/liv-SCID-Hu mice: a system for investigating the in vivo effects of multidrug therapy on plasma viremia and human immunodeficiency virus replication in lymphoid tissues. J Infect Dis (1998) 177(2):337-46. doi:10.1086/514214
172. Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J (1990) 9(5):1551-60.
173. Zack JA, Arrigo SJ, Weitsman SR, Go AS, Haislip A, Chen ISY. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell (1990) 61(2):213-22. doi:10.1016/0092-8674(90)90802-L
174. Brooks DG, Kitchen SG, Kitchen CMR, Scripture-Adams DD, Zack JA. Generation of HIV latency during thymopoiesis. Nat Med (2001) 7(4):459-64. doi:10.1038/86531
175. Scripture-Adams DD, Brooks DG, Korin YD, Zack JA. Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J Virol (2002) 76(24):13077-82. doi:10.1128/JVI.76.24.13077-13082.2002
176. Korin YD, Brooks DG, Brown S, Korotzer A, Zack JA. Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J Virol (2002) 76(16):8118-23. doi:10.1128/JVI.76.16.8118-8123.2002
177. Brooks DG, Hamer DH, Arlen PA, Gao L, Bristol G, Kitchen CM, et al. Molecular characterization, reactivation, and depletion of latent HIV. Immunity (2003) 19(3):413-23. doi:10.1016/S1074-7613(03)00236-X
178. Arlen PA, Brooks DG, Gao LY, Vatakis D, Brown HJ, Zack JA. Rapid expression of human immunodeficiency virus following activation of latently infected cells. J Virol (2006) 80(3):1599-603. doi:10.1128/JVI.80.3.1599-1603.2006
179. Choudhary SK, Archin NM, Cheema M, Dahl NP, Garcia JV, Margolis DM. Latent HIV-1 infection of resting CD4+ T cells in the humanized Rag2-/-γc-/-mouse. J Virol (2012) 86(1):114-20. doi:10.1128/JVI.05590-11
180. Holt N, Wang J, Kim K, Friedman G, Wang X, Taupin V, et al. Zinc finger nuclease-mediated CCR5 knockout hematopoietic stem cell transplantation controls HIV-1 in vivo. Nat Biotechnol (2010) 28(8):839-47. doi:10.1038/nbt.1663
181. Kumar P, Ban HS, Kim SS, Wu H, Pearson T, Greiner DL, et al. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell (2008) 134(4):577-86. doi:10.1016/j.cell.2008.06.034
182. Halper-Stromberg A, Lu C-L, Klein F, Horwitz JA, Bournazos S, Nogueira L, et al. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell (2014) 158(5):989-99. doi:10.1016/j.cell.2014.07.043
183. Denton PW, Olesen R, Choudhary SK, Archin NM, Wahl A, Swanson MD, et al. Generation of HIV latency in humanized BLT mice. J Virol (2012) 86(1):630-4. doi:10.1128/JVI.06120-11
184. Marsden MD, Kovochich M, Suree N, Shimizu S, Mehta R, Cortado R, et al. HIV latency in the humanized BLT mouse. J Virol (2012) 86(1):339-47. doi:10.1128/JVI.06366-11
185. Watkins RL, Foster JL, Garcia JV. In vivo analysis of Nef's role in HIV-1 replication, systemic T cell activation and CD4+ T cell loss. Retrovirology (2015) 12:61. doi:10.1186/s12977-015-0187-z
186. Shimizu S, Ringpis G-E, Marsden MD, Cortado RV, Wilhalme HM, ElashoffD, et al. RNAi-mediated CCR5 knockdown provides HIV-1 resistance to memory T cells in humanized BLT mice. Mol Ther Nucleic Acids (2015) 4(2):e227. doi:10.1038/mtna.2015.3
187. Denton PW, Long JM, Wietgrefe SW, Sykes C, Spagnuolo RA, Snyder OD, et al. "Targeted cytotoxic therapy kills persisting HIV infected cells during ART." Edited by Daniel C. Douek. PLoS Pathog (2014) 10(1):e1003872. doi:10.1371/journal.ppat.1003872
188. Honeycutt JB, Wahl A, Archin N, Choudhary S, Margolis D, Garcia J. HIV-1 infection, response to treatment and establishment of viral latency in a novel humanized T cell-only mouse (TOM) model. Retrovirology (2013) 10:121. doi:10.1186/1742-4690-10-121
189. Burkhard MJ, Dean GA. Transmission and immunopathogenesis of FIV in cats as a model for HIV. Curr HIV Res (2003) 1(1):15-29. doi:10.2174/1570162033352101
190. Kanzaki LI, Looney DJ. Feline immunodeficiency virus: a concise review. Front Biosci (2004) 9(January):370-7. doi:10.2741/1235
191. Elder JH, Lin Y-C, Fink E, Grant CK. Feline immunodeficiency virus (FIV) as a model for study of lentivirus infections: parallels with HIV. Curr HIV Res (2010) 8(1):73-80. doi:10.2174/157016210790416389
192. Mohammadi H, Bienzle D. Pharmacological inhibition of feline immunodeficiency virus (FIV). Viruses (2012) 4(5):708-24. doi:10.3390/v4050708
193. Wongsrikeao P, Saenz D, Rinkoski T, Otoi T, Poeschla E. AIDS virus restriction factor transgenesis in the domestic cat. Nat Methods (2011) 8(10):853-9. doi:10.1038/nmeth.1703
194. McDonnel SJ, Liepnieks ML, Murphy BG. Treatment of chronically FIV-infected cats with suberoylanilide hydroxamic acid. Antiviral Res (2014) 108(August):74-8. doi:10.1016/j.antiviral.2014.05.014
195. Sparger EE. "FIV as a model for HIV: an overview." In vivo models of HIV disease and control. In: Friedman H, Specter S, Bendinelli M, editors. Infectious Diseases and Pathogenesis. US: Springer (2006). p. 149-237.
196. Shimojima M, Miyazawa T, Ikeda Y, McMonagle EL, Haining H, Akashi H, et al. Use of CD134 as a primary receptor by the feline immunodeficiency virus. Science (2004) 303(5661):1192-5. doi:10.1126/science.1092124
197. Dean GA, Reubel GH, Moore PF, Pedersen NC. Proviral burden and infection kinetics of feline immunodeficiency virus in lymphocyte subsets of blood and lymph node. J Virol (1996) 70(8):5165-9.